Login to Your Account

Funds Are Stretched Thin

AMT Prepares for Glybera's Phase III Extension Study

By Nuala Moran

Friday, September 2, 2011
LONDON – Amsterdam Molecular Therapeutics (AMT) NV is now poised to begin the Phase III extension study of Glybera, its gene therapy treatment for lipoprotein lipase deficiency, and is paring back expenditure as it awaits a response from the European Medicines Agency (EMA) to its request for a re-examination of the Glybera file.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription